Where does NewAmsterdam Pharma Company's cash flow data come from?

Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$203.82M+15.6%	-$241.6M-36.5%	-$176.94M-682%	-$22.63M+45.8%
Depreciation and amortization	$220K+94.7%	$113K+131%	$49K+444%	$9K+80.0%
Stock-based compensation	$59.43M+76.8%	$33.62M+36.8%	$24.57M+497%	$4.12M+231%
Amortization of debt issuance costs	-$1.41M-519%	-$227K—	——	——
Gain (loss) on sale of assets	——	——	——	——
Change in accounts payable	$5.3M—	——	$5.07M+5.4%	$4.81M-26.7%
Change in accrued liabilities	——	——	——	-$8.68M-376%
Change in deferred revenue	——	——	-$8.71M-147%	$18.43M—
Net cash from operating activities	-$147.78M+6.8%	-$158.56M-12.3%	-$141.22M-1,424%	$10.67M+136%
Capital expenditures	$246K-63.4%	$672K+2,700%	$24K-89.1%	$221K+821%
Net cash from investing activities	-$177.42M-182%	-$62.85M-261,767%	-$24K+89.1%	-$221K-821%
Proceeds from issuance of common stock	$29.47M+1,567%	$1.77M—	——	——
Net cash from financing activities	$29.52M-95.5%	$659.51M+7,300%	$8.91M-97.7%	$391.91M+363%
Effect of exchange rate changes on cash	$12.82M+288%	-$6.8M—	——	$5.25M+212%
Net increase (decrease) in cash	-$293.18M—	——	-$132.33M-133%	$402.35M+629%
Income taxes paid	——	$1K-96.3%	$27K—	——
Non-cash interest expense	-$1.41M-519%	-$227K—	——	——
Change In Fair Value Of Derivative Earnout And Warrants	$18.78M—	——	——	$1.04M—
Foreign currency remeasurement (loss) gain on debt	$13.14M+299%	-$6.6M-230%	$5.06M+152%	-$9.75M-671%
Gain/(loss) on dispositions, net	——	——	——	——
Accrued expenses and other liabilities	——	——	——	-$8.68M-376%
Deferred revenue	——	——	-$8.71M-147%	$18.43M—
Increase Decrease In Prepayments And Other Receivables	——	$17.46M—	——	$4.19M-20.0%
Noncash Rent Expense	——	$12K+100%	$6K-40.0%	$10K+400%
Payments Of Stock Issuance Costs	——	——	——	——
Proceeds From Warrant Exercises	$1.64M-88.1%	$13.76M+59.6%	$8.62M—	——
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	$12.82M+288%	-$6.8M—	——	$5.25M+212%
Issuance Of Earnout Shares Amount	——	——	——	——
Recognition Of Rou Asset	——	$562K—	——	——
Free cash flow	-$148.03M+7.0%	-$159.24M-12.7%	-$141.24M-1,452%	$10.44M+135%
Free cash flow	-$148.03M+7.0%	-$159.24M-12.7%	-$141.24M-1,452%	$10.44M+135%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does NewAmsterdam Pharma Company's cash flow data come from?: Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.